ELUT_OUT_1 [2025-04-02 15:50:58 -0400] 2145 Bytes | 614 tokens | Cum: 614 tkns (7.67% of 8k)
==========================================================================

We're scouting for winners today. Its 3:50:57 PM on Wed Apr 02, 2025 -0400 and I'm looking at Elutia (ELUT) up to 2.86 from 2.5

Help me investigate to see if its got potential or just another dud. So, I pulled together a bunch of data for you to look over real fast.

--- COMPANY PROFILE ---
Company: Elutia (ELUT)
IPO: IPO date unknown
Shares Outstanding: 36,550,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS

Here's the first list of news for Elutia:

C1 - Mar-27-25 04:05PM - Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro
C2 - Mar-25-25 04:05PM - Elutia Advances Scientific Leadership with Publication of New Study on Antibiotic-Eluting Biologic Envelope
C3 - Mar-06-25 04:05PM - Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro in Pilot Launch Sets the Stage for Full Commercial Roll-Out
C4 - Mar-05-25 07:30AM - Earnings To Watch: Elutia Inc (ELUT) Reports Q4 2024 Result
C5 - Feb-20-25 04:05PM - Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025
C6 - Feb-03-25 06:30AM - Elutia Announces $15.0 Million Registered Direct Offering
C7 - Jan-15-25 08:15AM - Elutia announces full U.S. commercial launch of EluPro
C8 - Jan-14-25 08:00AM - Elutia Announces Full Launch of EluPro Following Strong Initial Demand

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Elutia (ELUT)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

ELUT_OUT_3 [2025-04-02 15:50:59 -0400] 1113 Bytes | 344 tokens | Cum: 960 tkns (12.00% of 8k)
==========================================================================

Showing C3 (chunk 1 of 11): C3:
**Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro in Pilot Launch Sets the Stage for Full Commercial Roll-Out**
Date: Mar-06-25 04:05PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/06/3038609/0/en/Elutia-Announces-Fourth-Quarter-and-Full-Year-2024-Financial-Results-Strong-Demand-for-EluPro-in-Pilot-Launch-Sets-the-Stage-for-Full-Commercial-Roll-Out.html

March 06, 2025 16:05 ET| Source:Elutia Inc.Elutia Inc.

– Overall BioEnvelope sales up 18%, with same-center sales increasing 65% following EluPro commercialization –

SILVER SPRING, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial results for the fourth quarter and full year ended December 31, 2024.

“Elutia

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ELUT_OUT_5 [2025-04-02 15:51:00 -0400] 902 Bytes | 274 tokens | Cum: 1236 tkns (15.45% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-31T17:17:28Z - Elutia Inc. (NASDAQ:ELUT) Sees Large Drop in Short Interest...
A2 - 2025-03-31T10:58:28Z - Elutia Inc. (NASDAQ:ELUT) Holdings Raised by AIGH Capital Management LLC...
A3 - 2025-03-27T20:18:10Z - Elutia Inc. secures deal with Advantus Health Partners By Investing.com...
A4 - 2025-03-27T20:18:10Z - Elutia Inc. secures deal with Advantus Health Partners By Investing.com...
A5 - 2025-03-27T20:25:06Z - Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ELUT_OUT_7 [2025-04-02 15:51:03 -0400] 1098 Bytes | 329 tokens | Cum: 1567 tkns (19.59% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**Elutia Inc. (NASDAQ:ELUT) Sees Large Drop in Short Interest**Date: 2025-03-31Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/elutia-inc-nasdaqelut-sees-large-drop-in-short-interest-2025-03-30/Elutia Inc. (NASDAQ:ELUT - Get Free Report) was the recipient of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 47,300 shares, a decrease of 30.1% from the February 28th total of 67,700 shares. Based on an average daily volume of 45,300 shares, the days-to-cover ratio is currently 1.0 days. Currently, 0.2% of the shares of the company are short sold.

Separately, Cantor Fitzgerald reissued an "overweight" rating and issued a $8.00 price objective on shares of Elutia in a research note on Friday, March 7th.

Read Our Latest Stock Analysis on ELUT

In re

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ELUT_OUT_9 [2025-04-02 15:51:04 -0400] 954 Bytes | 310 tokens | Cum: 1977 tkns (24.71% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-06-27T11:06:00Z - Zacks.com featured highlights BRC, Costamare and Elutia
B2 - 2024-06-26T11:18:00Z - 3 Best Breakout Stocks Worth a Buy for Attractive Returns
B3 - 2024-06-17T12:01:00Z - Elutia Announces $13.26 Million Registered Direct Offering
B4 - 2024-06-17T12:00:00Z - Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators
B5 - 2024-04-24T20:05:00Z - Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1
B6 - 2024-02-22T21:05:00Z - Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ELUT_OUT_11 [2025-04-02 15:51:08 -0400] 1110 Bytes | 316 tokens | Cum: 2295 tkns (28.69% of 8k)
==========================================================================

Showing B3 (chunk 1 of 2): B3:
**Elutia Announces $13.26 Million Registered Direct Offering**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/06/17/2899620/0/en/Elutia-Announces-13-26-Million-Registered-Direct-Offering.htmlSILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase and sale of 3,175,000 shares of the Company’s Class A common stock at a purchase price of $3.40 per share and 725,000 prefunded warrants to purchase up to 725,000 shares of the Company’s Class A common stock at a purchase price of $3.399 per prefunded warrant in a registered direct offering. The prefunded warrants are immediately exercisable at an exercise price of $0.001 per each prefunded warrant. The gross proceeds to Elutia from the offering are expe

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ELUT_OUT_13 [2025-04-02 15:51:09 -0400] 1094 Bytes | 284 tokens | Cum: 2701 tkns (33.76% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S3 - 2025-03-11 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

The following discussion and analysis should be read in conjunction with our CONS financial statements and the related notes included elsewhere in this Annual Report. This disc...

S7 - 2025-03-06 8-K Item 2.02 Results of Oper and Fin Cond.

On March 6, 2025, Elutia Inc. (the Company or Elutia) issued a press release announcing its results for the fourth quarter and full year ended December 31, 2024. A copy of the Companys press release is furnished as Exhibi...

S8 - 2025-02-04 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On February 3, 2025, Elutia Inc. (the Company) entered into a placement agency agreement (the Placement Agency Agrmt) with Lake Street Capital Markets, LLC (Placement Agent) and a securities purchase agreement (the Purch...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ELUT_OUT_15 [2025-04-02 15:51:09 -0400] 1098 Bytes | 229 tokens | Cum: 2932 tkns (36.65% of 8k)
==========================================================================

Showing S3 (chunk 1 of 6): S3:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis should be read in conjunction with our consolidated financial statements and the related notes included elsewhere in this Annual Report. This discussion contains forward-looking statements reflecting our current expectations, estimates, plans and assumptions concerning events and financial trends that involve risks and may affect our future operating results and financial position. Actual results and the timing of events may differ materially from those contained in these forward-looking statements due to a number of factors, including those discussed in the sections entitled Forward-Looking Statements, Risk Factors Summary and in Part I, Item 1A. Risk Factors of this Annual Report.

Overview

At Elutia, our mission is to humanize medicine so that pati

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ELUT_OUT_17 [2025-04-02 15:51:13 -0400] 1098 Bytes | 233 tokens | Cum: 3167 tkns (39.59% of 8k)
==========================================================================

Showing S3 (chunk 2 of 6): ents can thrive without compromise. As a commercial-stage company, we seek to leverage our unique understanding of biologics combined with local drug delivery to improve the interaction between implanted medical devices and patients by reducing complications associated with these surgeries. These complications include infection, device migration, erosion, implant rejection, non-union of implants, fibrosis and scar formation.

We estimate that in 2024, more than 700,000 surgical procedures were performed annually in the United States involving the implantation of medical devices such as pacemakers, defibrillators, neurostimulators or tissue expanders for breast reconstruction. This number has been driven by advances in medical device technologies, reimbursement models focused on patient outcomes, and an aging population with a growing incidence of comorbidities, including diabetes, obesi

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ELUT_OUT_19 [2025-04-02 15:51:19 -0400] 1098 Bytes | 226 tokens | Cum: 3495 tkns (43.69% of 8k)
==========================================================================

Showing S3 (chunk 3 of 6): ty and cardiovascular and peripheral vascular diseases. These comorbidities can exacerbate various immune responses and contribute to other complications upon device implant.

Our products are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar tissue formation, capsular contraction, erosion, migration and infection. We currently focus on two priority markets Device Protection and Womens Health.

In Device Protection, we sell EluPro, a unique bioenvelope designed to mitigate CIED complications including infection, device migration and erosion. The bioenvelope features a biomatrix comprised of ECM, which supports healthy wound healing and may facilitate re-operative procedures by reducing scar formation and fibrosis. Additionally, EluPro is embedded with the powerful

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ELUT_OUT_21 [2025-04-02 15:51:28 -0400] 5407 Bytes | 1620 tokens | Cum: 5244 tkns (65.55% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+------------------------+
| Volume: 8,181 | Perf Month: -3.38% | Option/Short: No / Yes | Sales Y/Y TTM: -31.04% |
+--------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 41.60K | Perf Quarter: -26.48% | Short Float: 0.19% | ROE: - |
+--------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 0.21 | Index: - | Short Ratio: 1.14 | ROI: - |
+--------------------+-----------------------+------------------------+------------------------+
| RSI (14): 49.02 | Market Cap: 116.87M | Short Interest: 0.05M | Sales Surprise: -7.32% |
+--------------------+-----------------------+------------------------+------------------------+
| ATR (14): 0.27 | Shs Outstand: 30.90M | Beta: 0.96 | EPS Surprise: -4.00% |
+--------------------+-----------------------+------------------------+------------------------+
| SMA20: -1.10% | Shs Float: 25.05M | Sales Q/Q: -6.93% | P/E: - |
+--------------------+-----------------------+------------------------+------------------------+
| SMA50: -2.93% | Inst Own: 29.98% | Sales past 5Y: -7.38% | Earnings: Mar 06 AMC |
+--------------------+-----------------------+------------------------+------------------------+
| SMA200: -20.80% | Insider Own: 38.70% | Employees: 51 | |
+--------------------+-----------------------+------------------------+------------------------+
| Perf Week: 10.00% | Insider Trans: 5.61% | Debt/Eq: - | |
+--------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: ELUTIA INC. (ELUT) by HighCape Capital, L.P. (Unknown Title) on 2025-02-03
- Class A Common Stock: 420000 shares at $2.5 (I)

Inside Trans: ELUTIA INC. (ELUT) by HighCape Capital, L.P. (Unknown Title) on 2025-02-03
- Class A Common Stock: 420000 shares at $2.5 (I)

Inside Trans: ELUTIA INC. (ELUT) by Williams Michelle LeRoux (CHIEF SCIENTIFIC OFFICER) on 2025-03-10
- Class A Common Stock: 12500 shares at $N/A (D)
- Class A Common Stock: 4613 shares at $3 (D)
- Restricted Stock Units: 12500 shares at $0 (D)

Inside Trans: ELUTIA INC. (ELUT) by Mills C Randal (PRESIDENT AND CEO) on 2025-03-10
- Class A Common Stock: 27083 shares at $N/A (D)
- Class A Common Stock: 10706 shares at $3 (D)
- Restricted Stock Units: 27083 shares at $0 (D)

Inside Trans: ELUTIA INC. (ELUT) by Ferguson Matthew (CHIEF FINANCIAL OFFICER) on 2025-03-08
- Class A Common Stock: 1287 shares at $N/A (D)
- Class A Common Stock: 528 shares at $2.77 (D)
- Class A Common Stock: 29000 shares at $N/A (D)
- Class A Common Stock: 11885 shares at $3 (D)
- Restricted Stock Units: 12500 shares at $0 (D)
- Restricted Stock Units: 16500 shares at $0 (D)
- Restricted Stock Units: 1287 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 24375000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -53949000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 2.86
Average Volume: 48410.52
30-Day High: 3.28
30-Day Low: 2.5

[Detailed Financials: TTM 2024]
- Total Assets: $36,127,000.0
- Total Liabilities: $82,387,000.0
- Total Equity: $-46,260,000.0
- Current Assets: $26,172,000.0
- Current Liabilities: $37,795,000.0

[Income Statement: TTM 2024]
- Revenue: $24,375,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -1.86

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-6,037,000.0

[Detailed Financials: FY 2024]
- Total Assets: $36,127,000.0
- Total Liabilities: $82,387,000.0
- Total Equity: $-46,260,000.0
- Current Assets: $26,172,000.0
- Current Liabilities: $37,795,000.0

[Income Statement: FY 2024]
- Revenue: $24,375,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -1.86

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-6,037,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

ELUT_OUT_23 [2025-04-02 15:51:30 -0400] 676 Bytes | 167 tokens | Cum: 5651 tkns (70.64% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

ELUT_IN_25 [2025-04-02 15:51:30 -0400] 126 Bytes | 29 tokens | Cum: 5708 tkns (71.35% of 8k)
==========================================================================

====================================
[2025-04-02 15:51:30] # Analysis Completed
Elapsed Time: 33.17 seconds